The study consists of a screening period, a run-in period, a 6-months core treatment period, a 7-months extension treatment period and a safety follow-up period.
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with SBS-associated intestinal failure (SBS-IF).